Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17125039 | 0.94 | TSHR (0.36) | DPP4CYP3A4EPHX2TSHRHSD17B10 | |
| SCHEMBL25857186 | 0.87 | GAA (0.43) | DPP4EPHX2TSHR | |
| SCHEMBL28576192 | 0.84 | TSHR (0.39) | DPP4CYP3A4EPHX2TSHRHSD17B10 | |
| SCHEMBL25857225 | 0.81 | DPP4 (0.36) | DPP4TSHRCETP | |
| SCHEMBL23513339 | 0.81 | DPP4 (0.35) | DPP4CYP3A4EPHX2TSHRHSD17B10 | |
| SCHEMBL15620816 | 0.79 | TSHR (0.36) | DPP4CYP3A4EPHX2TSHRHSD17B10 | |
| SCHEMBL23513275 | 0.78 | DPP4 (0.34) | DPP4CYP3A4EPHX2TSHRHSD17B10 | |
| Bromide SCHEMBL28562616 | 0.77 | DPP4 (0.33) | DPP4CYP3A4EPHX2TSHRHSD17B10 | |
| SCHEMBL28873044 | 0.76 | GAA (0.39) | DPP4EPHX2TSHR | |
| SCHEMBL4159695 | 0.74 | CYP3A4 (0.40) | CYP3A4EPHX2TSHRHSD17B10TET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | G1 THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | NDC1, SDC1, SDC2 | DPP4 1311/4885CYP3A4 2779/4885EPHX2 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.